We herein present the case of a 58-year-old Japanese man with Fanconi's syndrome with a 13-month history of bone pain in his ribs, hips, knees and ankles. He had been receiving low-dose adefovir dipivoxil (ADV) for the treatment of lamivudine-resistant chronic hepatitis B virus infection for eight years and subsequently developed severe hypophosphatemia and proximal renal tubule dysfunction. Magnetic resonance imaging showed multiple insufficiency fractures in the ribs, ileum, tibia and calcaneus. Whole-body bone scintigraphy demonstrated increased uptake in those areas. Following dose reduction of ADV and the administration of treatment with calcitriol and phosphates, the patient's serum phosphate level increased and his clinical symptoms improved. Physicians prescribing ADV should carefully monitor the renal function and serum phosphate level.
Introduction
Adefovir dipivoxil (ADV) is a commonly used antiviral agent in the treatment of chronic hepatitis B virus (HBV) or human immunodeficiency virus (HIV) infection. Although high-dose ADV therapy (60-120 mg/day) is nephrotoxic (1), low-dose ADV therapy (10 mg/day) has been reported to be safe (2-7). However, there is an increasing number of reports stating that the long-term use of low-dose ADV causes proximal renal tubular dysfunction, a feature of Fanconi's syndrome, especially in East Asian populations (8-24). We herein report a case of severe hypophosphatemic osteomalacia with Fanconi's syndrome caused by low-dose ADV for the treatment of chronic hepatitis B virus infection. The patient was 56.0 kg in weight and 161.6 cm in height and had a body mass index of 21.4 kg/m 2 . His heart rate was 78 bpm and his blood pressure was 128/74 mmHg. On a physical examination, he had generalized bone tenderness, especially in the regions mentioned above. No strumas were palpable. There were no specific signs in the respiratory, digestive or circulatory systems. There was no edema in the patient's legs. The laboratory data revealed hypophosphatemia (1.39 mg/dL; normal range 2.5-4.5 mg/dL), hypouricemia (2.82 mg/dL; normal range 3.60-7.00 mg/dL) and increased levels of alkaline phosphatase (ALP, 921 U/L; normal range 115-359 U/L) and bone alkaline phosphatase (BAP, 76.1 U/L; normal range 3.7-20.9 μg/L). The serum creatinine level was normal (1.06 mg/dL; normal range 0.6-1.10 mg/dL). However, it gradually increased up to 1.23 mg/dL. The serum calcium (9.62 mg/dL), intact parathyroid hormone (PTH, 26 pg/mL; normal range 10-65 mg/dL) and 1,25 dihydroxyvitamin D (46.4 pg/mL; normal range 20.0-60.0 pg/mL; 1,25-hydroxyvitamin D RIA kit 'TFB'; Immunodiagnostic Systems Ltd., Boldon, UK) levels were all within the normal range. The serum fibroblast growth factor 23 level was low (3.8 pg/mL; normal range 10-50 pg/mL; FGF23 ELISA kit; Kainos Laboratories, Inc., Tokyo, Japan) (25). The serum FT3 level was 3.0 pg/mL (1.9-3.5 pg/ mL) and the FT4 level was 0.90 (0.88-1.56 ng/dL), both within the normal range; however, the TSH (5.67 μU/mL; normal range 0.210-3.850 μU/mL) level was slightly elevated. Anti-thyroid peroxidase (TPO) antibodies were positive (353.3 IU/mL; normal range <5.0 IU/mL). There was no metabolic acidosis. The patient's blood HCO3 -was 22.7 mEq/L. A urinalysis showed proteinuria (100 mg/dL), glucosuria (250 mg/dL) and general aminoaciduria. These findings suggested that the patient had Fanconi's syndrome and chronic thyroiditis. Magnetic resonance imaging (MRI) revealed multiple insufficiency fractures in the bilateral ribs, ileum, right femur, left distal tibia and left calcaneus. Tchydroxymethylene diphosphonate (HMDP) scintigraphy demonstrated significant abnormal uptake in the ribs, left shoulder, pelvis, right knee and left ankle and heel (Fig. 1) . We diagnosed the patient with osteomalacia due to Fanconi's syndrome secondary to ADV therapy for chronic hepatitis B and chronic thyroiditis. Following the reduction of the dose of ADV from 10 mg every day to every other day with supplementation with alfacalcidol (4 μg/day) and phosphate (1.5 g/day), the patient's serum phosphate and creatinine levels normalized, and both the glycosuria and proteinuria resolved (Fig. 2) . Clinical symptoms, such as bone pain, also disappeared.
Discussion
ADV, a nucleotide analog widely used in the management of patients with chronic hepatitis B, can be nephrotoxic, even at low doses. ADV-induced nephrotoxicity is dosedependent. The incidence of an increase in the level of cre- atinine of greater than 0.5 mg/mL from baseline is 35% at 48 weeks and 50% at 72 weeks in patients receiving 120 mg/day of ADV (1). Hypophosphatemia occurs in 50% of patients after 48 weeks and 61% of patients after 72 weeks of ADV treatment (1) . Among patients treated with 30 mg of ADV, 21% exhibit an increase in creatinine of more than 0.5 mg/dL from baseline by week 48, while 16% are hypophosphatemic (6). Conversely, a 10-mg/day dose of ADV is generally well tolerated, with no increases in adverse events or laboratory abnormalities compared with a placebo, as reported in two registered trials (2, 3) . In subsequent studies, the incidence of an increase in serum creatinine of 0.5 mg/ dL or more has been reported to occur in 2-8% of patients on long-term ADV therapy (4-7, 26-29). However, this is not the case in the Japanese population. Tamori et al. (10) reported that the serum creatinine levels increased in 14 (38%) of 37 patients, while the serum phosphate levels decreased to below 2.5 mg/mL in six (16%) of 37 patients during therapy. There is an increasing number of case reports from East Asian countries that show that even patients on low-dose ADV exhibit nephrotoxicity (Table) . The ages of these patients varied from 22 to 74 years, with a median of 56 years. The male/female ratio was 4.5. Symptoms became clinically evident after a median of 36 months (range 6-71 months). Muscle weakness and generalized bone pain were the major symptoms. Following discontinuation or reduction of the dose of ADV, the serum phosphate levels and clinical symptoms improved in almost all cases, suggesting that ADV-induced nephrotoxicity is reversible.
ADV-induced nephrotoxicity is characterized by a decrease in the level of phosphate and a slight increase in the level of creatinine, resulting in renal proximal tubular dysfunction, the features of Fanconi's syndrome (30). Although the mechanisms underlying the development of ADVinduced nephrotoxicity are not fully understood, ADV may cause apoptosis or mitochondrial toxicity of the renal tubular epithelium (31). The human organic anion transporter-1 (hOAT1), a basolateral membrane protein of the proximal tubule, mediates the active uptake of ADV from the blood into proximal tubular cells (32). ADV is secreted into the urine by multidrug resistance proteins (MRPs) 2, 4 and 5, which are located on the apical side of proximal tubular cells (33). The overexpression of hOAT1 or underexpression of MRPs, therefore, may result in the accumulation of ADV in the renal tubules and subsequent tubular toxicity. Genetic polymorphisms, which affect the expression of these proteins, may contribute to ADV-induced nephrotoxicity (34, 35).
In conclusion, we herein reported a case of severe hypophosphatemic osteomalacia with Fanconi's syndrome caused by the long-term use of low-dose ADV for the treatment of chronic hepatitis B. There is an increasing number of similar reports from East Asian countries, suggesting that ethnic factors or an increased number of patients with persistent HBV infection in these areas may influence the development 
